Effectiveness and Safety of Non-Vitamin K Oral Anticoagulants versus Warfarin in Patients with Atrial Fibrillation and Previous Stroke: A Systematic Review and Meta-Analysis
Neuroepidemiology · 2024 · 58 (1) · 1-14
DOI: 10.1159/000534596 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Neuroepidemiology, online erschienen am 17.10.2023. Verfasst von Minglei Shi und 4 weiteren Autor:innen. Beteiligte Einrichtung: School of Life Course and Population Sciences, King's College London, London, UK. Hauptthemen laut MEDLINE: Warfarin, Atrial Fibrillation, Anticoagulants, Stroke. Die Arbeit wurde bisher 4-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Themen: Schlaganfall
Abstract (Originalsprache)
Introduction
Current evidence regarding the clinical outcomes of non-vitamin K oral anticoagulants (NOACs) versus warfarin in patients with atrial fibrillation (AF) and previous stroke is inconclusive, especially in patients with previous intracranial haemorrhage (ICrH). We aim to undertake a systematic review and meta-analysis assessing the effectiveness and safety of NOACs versus warfarin in AF patients with a history of stroke.
Methods
We searched studies published up to December 10, 2022, on PubMed, Medline, Embase, and Cochrane Central Register of Controlled Trials. Studies on adults with AF and previous ischaemic stroke (IS) or IrCH receiving either NOACs or warfarin and capturing outcome events (thromboembolic events, ICrH, and all-cause mortality) were eligible for inclusion.
Results
Six randomized controlled trials (RCTs) (including 19,489 patients with previous IS) and fifteen observational studies (including 132,575 patients with previous IS and 13,068 patients with previous ICrH) were included. RCT data showed that compared with warfarin, NOACs were associated with a significant reduction in thromboembolic events (odds ratio [OR]: 0.85, 95% confidence interval [CI]: 0.75–0.96), ICrH (OR: 0.57, 95% CI: 0.36–0.90), and all-cause mortality (OR: 0.88, 95% CI: 0.80–0.98). In analysing observational studies, similar results were retrieved. Moreover, patients with previous ICrH had a lower OR on thromboembolic events than those with IS (OR: 0.66, 95% CI: 0.46–0.95 vs. OR: 0.80, 95% CI: 0.70–0.93) in the comparison between NOACs and warfarin.
Conclusions
Observational data showed that in AF patients with previous stroke, NOACs showed better clinical performance compared to warfarin and the benefits of NOACs were more pronounced in patients with previous IrCH versus those with IS. RCT data also showed NOACs are superior to warfarin. However, current RCTs only included AF patients who survived an IS, and further large RCTs focused on patients with previous ICrH are warranted.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Life Course and Population Sciences, King's College London, London, UK.
Zitieren
APA
Shi, M., Liu, L., Wafa, H., Curcin, V., & Wang, Y. (2024). Effectiveness and Safety of Non-Vitamin K Oral Anticoagulants versus Warfarin in Patients with Atrial Fibrillation and Previous Stroke: A Systematic Review and Meta-Analysis. Neuroepidemiology, 58(1), 1-14. https://doi.org/10.1159/000534596
Vancouver
Shi M, Liu L, Wafa H, Curcin V, Wang Y. Effectiveness and Safety of Non-Vitamin K Oral Anticoagulants versus Warfarin in Patients with Atrial Fibrillation and Previous Stroke: A Systematic Review and Meta-Analysis. Neuroepidemiology. 2024;58(1):1-14. doi:10.1159/000534596
BibTeX
@article{Shi2024,
author = {Shi, Minglei and Liu, Lu and Wafa, Hatem and Curcin, Vasa and Wang, Yanzhong},
title = {Effectiveness and Safety of Non-Vitamin K Oral Anticoagulants versus Warfarin in Patients with Atrial Fibrillation and Previous Stroke: A Systematic Review and Meta-Analysis},
journal = {Neuroepidemiology},
year = {2024},
volume = {58},
number = {1},
pages = {1--14},
doi = {10.1159/000534596}
}
EUVIMED